AstraZeneca presents new data on renal portfolio at ASN Kidney Week 2020 Reimagined
AstraZeneca revealed a host of data at the virtual ASN Kidney Week 2020 Reimagined conference in line with its ambition to create a co-ordinated pathway for renal patients to advance earlier diagnosis or slow the progression of chronic kidney disease.
The company presented 84 abstracts, including three late-breaking ones and 12 oral presentations, across its renal portfolio, which includes roxadustat, Farxiga (dapagliflozin) and Lokelma (sodium zirconium cyclosilicate).
Sir Mene Pangalos , executive vice president, biopharmaceuticals R&D, said: “The breadth of data being presented by AstraZeneca demonstrates the growing momentum of our renal portfolio.
“Our ambition is to provide new treatments for hundreds of millions of patients with chronic kidney disease, a progressive condition for which there currently is no cure.
“We are particularly excited to share insights into the safety and efficacy of roxadustat in anaemia of chronic kidney disease (CKD) and new subgroup data from the DAPA-CKD trial looking at the benefit of Farxiga regardless of disease cause.”
AstraZeneca presented more than 40 abstracts on roxadustat at the conference, held from October 22-25, providing new insight on the potential of the medicine to transform the standard of care in anaemia of CKD across key patient sub-populations.
Meanwhile, late-breaking subgroup data was presented on Farxiga, which has been shown as the first medicine to significantly prolong survival in a renal outcomes trial in patients with CKD with and without type-2 diabetes.
Read more
AstraZeneca agrees potential $6bn oncology collaboration with Daiichi Sankyo
AstraZeneca’s new Cambridge Biomedical Campus HQ will be phenomenal, says Dr Mene Pangalos
Sign up for our weekly newsletter and stay up to date with Cambridge business
